The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Molecule Holdings are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Molecule Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Molecule Holdings is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Begin Period Cash Flow
902.5 K
Total Cashflows From Investing Activities
167 K
Free Cash Flow
-2.9 M
Molecule
Molecule Holdings Relative Risk vs. Return Landscape
If you would invest 0.25 in Molecule Holdings on November 4, 2025 and sell it today you would earn a total of 0.00 from holding Molecule Holdings or generate 0.0% return on investment over 90 days. Molecule Holdings is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Molecule, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
Expected Return
Risk
Molecule Holdings Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Molecule Holdings for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Molecule Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Molecule Holdings is not yet fully synchronised with the market data
Molecule Holdings has some characteristics of a very speculative penny stock
Molecule Holdings has a very high chance of going through financial distress in the upcoming years
Molecule Holdings has accumulated 817.09 K in total debt with debt to equity ratio (D/E) of 1.37, which is about average as compared to similar companies. Molecule Holdings has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Molecule Holdings until it has trouble settling it off, either with new capital or with free cash flow. So, Molecule Holdings' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Molecule Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Molecule to invest in growth at high rates of return. When we think about Molecule Holdings' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 455.26 K. Net Loss for the year was (4.23 M) with loss before overhead, payroll, taxes, and interest of (499.74 K).
Molecule Holdings has accumulated about 73.25 K in cash with (2.87 M) of positive cash flow from operations.
Roughly 17.0% of Molecule Holdings shares are held by company insiders
Molecule Holdings Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Molecule Pink Sheet often depends not only on the future outlook of the current and potential Molecule Holdings' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Molecule Holdings' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding
95.4 M
Short Long Term Debt
3.5 M
Shares Float
81.8 M
Molecule Holdings Fundamentals Growth
Molecule Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Molecule Holdings, and Molecule Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecule Pink Sheet performance.
By analyzing Molecule Holdings' fundamental ratios, stakeholders can gain valuable insights into Molecule Holdings' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Molecule Holdings has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Molecule Holdings has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Molecule Holdings Inc. engages in production and co-packing of cannabis-infused beverages in Canada. It offers its beverage products under the PHRESH, embody, and CANAJO brands. Molecule Holdings is traded on OTC Exchange in the United States.
Things to note about Molecule Holdings performance evaluation
Checking the ongoing alerts about Molecule Holdings for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Molecule Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Molecule Holdings is not yet fully synchronised with the market data
Molecule Holdings has some characteristics of a very speculative penny stock
Molecule Holdings has a very high chance of going through financial distress in the upcoming years
Molecule Holdings has accumulated 817.09 K in total debt with debt to equity ratio (D/E) of 1.37, which is about average as compared to similar companies. Molecule Holdings has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Molecule Holdings until it has trouble settling it off, either with new capital or with free cash flow. So, Molecule Holdings' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Molecule Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Molecule to invest in growth at high rates of return. When we think about Molecule Holdings' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 455.26 K. Net Loss for the year was (4.23 M) with loss before overhead, payroll, taxes, and interest of (499.74 K).
Molecule Holdings has accumulated about 73.25 K in cash with (2.87 M) of positive cash flow from operations.
Roughly 17.0% of Molecule Holdings shares are held by company insiders
Evaluating Molecule Holdings' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Molecule Holdings' pink sheet performance include:
Analyzing Molecule Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecule Holdings' stock is overvalued or undervalued compared to its peers.
Examining Molecule Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Molecule Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecule Holdings' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Molecule Holdings' pink sheet. These opinions can provide insight into Molecule Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Molecule Holdings' pink sheet performance is not an exact science, and many factors can impact Molecule Holdings' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Molecule Pink Sheet
If you are still planning to invest in Molecule Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Molecule Holdings' history and understand the potential risks before investing.